Andy Batts
Long only, value, growth, momentum

Fluidigm: Unique Investing Opportunity In Single-Cell Genomics

Fluidigm (NASDAQ:FLDM), a company that makes microfluidic systems consisting of instruments and consumables for use in life science and agricultural biotechnology research, has huge growth prospects in the emerging single-cell genomics ("SCG") market. The company has developed an innovative approach to SCG based on its microfluidics technology and going forward it aims to become a technology leader in single-cell biology.

Fluidigm recently announced that it will acquire DVS Sciences for offering its customers a comprehensive portfolio of advanced technologies across single-cell genomics and proteomics. Given that single-cell genomics is a nascent market with significant scope to grow, Fluidigm, the $1 billion company, could be a multi-bagger investing opportunity.

What is Single-Cell Genomics?

In single-cell genomics, genomic measurement technologies...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details